Note: Single-source report; awaiting corroboration.
A National Institutes of Health (NIH)-funded study from Cleveland Clinic found that male-associated hormones like testosterone may inhibit brain tumor growth in men, especially in glioblastoma cases. Researchers noted that the loss of androgens in mouse models led to increased tumor growth due to local inflammation and activation of stress hormone pathways.
Reducing androgens in the study activated the hypothalamus-pituitary-adrenal (HPA) axis, a neuroendocrine system, increasing stress hormones that limited immune cell access in the brain. This immunosuppressive environment allowed tumors to grow more freely. The effect was not seen in female mice, indicating a sex-specific mechanism in tumor progression.
Analysis of clinical data from over 1,300 male glioblastoma patients showed supplemental testosterone was significantly correlated with improved survival rates, supporting the preclinical findings. Researchers suggest that androgens regulate the brain’s immune defenses differently from their effects in other body regions.
Further research is planned to clarify how tumors provoke inflammation and neuroendocrine responses in brain areas distant from the tumor site, aiming to better understand and potentially use hormone pathways in glioblastoma treatment.
According to the NIH, these findings may open new avenues for therapies that target hormone regulation in a cancer type that disproportionately affects men.